Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Chloroquine
Chloroquine, Tafenoquine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Tafenoquine | ACTIVE_COMPARATOR | Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria. |
| Chloroquine | ACTIVE_COMPARATOR | Dose for first 3 days for Part B \& C of the study |
| Primaquine | ACTIVE_COMPARATOR | once daily for first 14 days |
| Part 1 | ACTIVE_COMPARATOR | Tafenoquine + Chloroquine vs. Chloroquine alone |
| Part 2 | PLACEBO_COMPARATOR | Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine |
| Name | Type | Description |
|---|---|---|
| Chloroquine | DRUG | The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up. |
| Primaquine | DRUG | Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment |
| Tafenoquine | DRUG | Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria |
| Chloroquine, Tafenoquine | DRUG | Chloroquine and Tafenoquine |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * A subject will be eligible for inclusion in this study only if all of the following criteria apply: * The subject is between 18 and 45 years of age, inclusive * A female is eligible to enter and participate in this study if she is non-pregnant, non-lactating and if she is of: ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | Tafenoquine, Primaquine, Chloroquine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
Chloroquine is used for malaria, including Plasmodium vivax malaria. It is being studied in combination with tafenoquine for the prevention of vivax relapse. Chloroquine is a small molecule developed by GSK plc for the infectious disease area.
Chloroquine targets the malaria parasite in red blood cells. It interferes with the parasite's ability to break down and detoxify heme, a byproduct of hemoglobin digestion, leading to toxic accumulation and parasite death. This mechanism is effective against blood-stage malaria parasites.
GSK plc (ticker: GSK) is developing Chloroquine. The company is conducting clinical trials to evaluate Chloroquine in combination with tafenoquine for malaria treatment and relapse prevention.
Chloroquine is in Phase 2 clinical development for malaria. It is an investigational drug in this context, though it has a long history of use. The Phase 2 trial, NCT01376167, is completed and evaluated tafenoquine plus chloroquine for preventing vivax relapse.
Chloroquine is associated with three completed trials: NCT00871156, a Phase 1 drug-drug interaction study with tafenoquine in healthy volunteers; NCT01205178, a Phase 1 G6PD study evaluating hemolysis potential; and NCT01376167, a Phase 2b/3 study in vivax malaria relapse prevention. Total enrollment across trials was 851 participants.
No, Chloroquine is not the same as tafenoquine. They are different drugs studied in combination. Chloroquine is a 4-aminoquinoline antimalarial, while tafenoquine is an 8-aminoquinoline. In clinical trials, they are used together to prevent relapse of Plasmodium vivax malaria.